Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare ...